1-4 of 4
Matthew James Butler
Close
Sort by
Journal Articles

Classical Hematology Referrals at an NCI-Designated Cancer Center: Lessons Learned

Chase West, Matthew James Butler, Supreet Kaur, Anand Karnad
Journal: Blood
Blood (2022) 140 (Supplement 1): 5025–5026.
https://doi.org/10.1182/blood-2022-158377
Published: 2022
Journal Articles

Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients

Adolfo Enrique Diaz Duque, Anand Karnad, Matthew James Butler, Elizabeth Bowhay-Carnes, Joel E Michalek, Gabriela Huelgas, Ricardo Aguiar
Journal: Blood
Blood (2022) 140 (Supplement 1): 6610–6611.
https://doi.org/10.1182/blood-2022-167001
Published: 2022
Journal Articles

Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients

Adolfo E Diaz, MD, Matthew James Butler, MD, Anand Karnad, MD, Ricardo Aguiar, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1592.
https://doi.org/10.1182/blood-2019-124382
Published: 2019
Journal Articles

Prognostic Factors and Survival Outcomes in Phase I Patients with Hematologic Malignancies

Matthew James Butler, MD, Josephine A Taverna, MD, Zuxi Cui, MS, Jiao Yu, MA, Joel E Michalek, PhD, Alex Bokov, PhD, Laura S Manuel, Amelie G Ramirez, DrPH, Alex V. Mejia, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3452.
https://doi.org/10.1182/blood.V130.Suppl_1.3452.3452
Published: 2017